XML 339 R46.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue recognition (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Summary of Disaggregation of Revenue The Company's revenues disaggregated by the major sources were as follows:
Year Ended December 31,
2024
2023
2022
USGNon-USGTotalUSGNon-USGTotalUSGNon-USGTotal
Commercial Product sales$0.8 $398.1 $398.9 $0.8 $496.5 $497.3 $0.8 $385.8 $386.6 
MCM Product sales381.3 128.5 509.8 373.5 73.7 447.2 444.6 135.0 579.6 
Bioservices:
Services (1)
— 103.5 103.5 — 72.8 72.8 — 105.0 105.0 
Leases— 1.4 1.4 — 5.7 5.7 — 4.9 4.9 
Total Bioservices$— $104.9 $104.9 $— $78.5 $78.5 $— $109.9 $109.9 
Contracts and grants28.4 1.6 30.0 20.4 5.9 26.3 37.2 4.2 41.4 
Total revenues$410.5 $633.1 $1,043.6 $394.7 $654.6 $1,049.3 $482.6 $634.9 $1,117.5 
(1) Bioservices Services revenues for the year ended December 31, 2024 include $50.0 million attributable to the Settlement Agreement with Janssen related to the 2022 termination of the Janssen Agreement. The revenue is related to raw materials purchased for the Janssen Agreement which Janssen had not reimbursed. See Note 19, “Litigation” for additional information related to the accounting treatment and settlement of the arbitration with Janssen.
Schedules of Concentration of Risk, by Risk Factor
For the years ended December 31, 2024, 2023 and 2022, the Company's product sales from NARCAN®, Other Commercial products, Anthrax MCM, Smallpox MCM and Other products as a percentage of total product sales were as follows:
Year Ended December 31,
202420232022
% of product sales:   
Commercial Products:
NARCAN®
44 %51 %39 %
Other Commercial products— %1 %1 %
MCM Products:
Anthrax MCM15 %20 %30 %
Smallpox MCM31 %18 %24 %
Other Products10 %10 %6 %
Summary of Deferred Revenue Contract Liabilities The following table presents the roll forward of the contract liabilities:
 Contract Liabilities
Balance at December 31, 2023$29.9 
Balance at December 31, 2024$9.3 
Revenue recognized in the period from amounts included in contract liability at the beginning of the period:$26.2 
Schedule of Accounts Receivable, Net
Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:
 December 31,
20242023
Accounts receivable:
Billed$135.4 $141.8 
Unbilled19.6 51.4 
Allowance for expected credit losses(0.5)(2.2)
Accounts receivable, net$154.5 $191.0